Business Strategy
 
 Focused on CNS area

Specialized technological expertise in the fields of neuropathic pain and Alzheimer's disease

 
·  Non-narcotic analgesics
 
 
·  Topical treatment for neuropathic pain
·  Chronic obstructive pulmonary disease
 
 
·  Treatment for Alzheimer’s disease

 Partnering Strategy for Risk Management

  •  Out license to multinational pharmaceutical companies as early as possible
  •  To reduce clinical costs and further expenses
  •  To share global pharma’s experiences
  •  To increase likelihood of success
  •   (Risk minimization, success possibility UP)

·  Neuropathic pain
  (Strong analgesics)
·  Alzheimer's disease
Big Pharma’s interest
 
Out license
 
Co-development